Back
 JBM  Vol.5 No.3 , March 2017
Relationship of Density of Specific Prostate Antigen (DPSA) with Prostate Histopathology: A Comparative Study of Patients Addressed in a School Hospital
Abstract: Background: The prostate is the site of problems that have great clinical relevance. Beside this, the alterations in their volume can be divided into benign or malignant pathologies, but of multifactorial cause and there is no examination that alone is reliable for the diagnosis. Despite the evolution of the various methods of diagnostic imaging in the evaluation of pelvic diseases, the diagnosis of prostate cancer still requires histological confirmation obtained by transrectal ultrasound guided biopsy, a procedure that is generally safe and well tolerated by the patients. The most common histological type found in prostate biopsies is adenocarcinoma. Methodology: The objective of this study was to study the values of density of the prostate-specific antigen (DPSA) compared to histopathological results of prostate biopsy, patients attended at the Urology Outpatient Clinic of the Luiz Gioseffi Jannuzzi School Hospital from 1999 to 2007, using Exploratory, retrospective and documentary descriptive study. The sample was divided into groups of patients with adenocarcinoma and patients without adenocarcinoma, who presented only benign prostatic hyperplasia. Results: Of the 251 patients undergoing prostate biopsy, 124 were diagnosed with adenocarcinoma and 127 without adenocarcinoma. It was observed in this study that the DPSA was higher in adenocarcinoma than in the cases of patients with prostatic hyperplasia alone, and could therefore be used as an auxiliary tool in both diagnosis and follow-up of patients with adenocarcinoma. Conclusion: In this study, it can be observed that DPSA was higher in patients presenting with adenocarcinoma than in patients presenting only Benign Prostatic Hyperplasia (BPH), reinforcing its promising role to assist in the diagnosis and follow-up of patients with adenocarcinoma.
Cite this paper: Brandão, M. , Brandão, M. , Sathler, E. , Vieira, R. , Vieira, C. , de Alencar, P. , de Mello Pinto, M. , Rocha, L. , Lopes, L. , da Costa, D. and Branco, C. (2017) Relationship of Density of Specific Prostate Antigen (DPSA) with Prostate Histopathology: A Comparative Study of Patients Addressed in a School Hospital. Journal of Biosciences and Medicines, 5, 105-111. doi: 10.4236/jbm.2017.53011.
References

[1]   Moore, K.L. and Dalley, A.F. (2007) Anatomia orientada para a clínica. 4a ed., 326.

[2]   Tanagho, A. and McAninch, J.W.S. (1994) Urologia geral. 13a ed., 303.

[3]   Sócrates de Castro, H.A., et al. (2011) Contribuição da densidade do PSA para predizer o câncer de próstata em pacientes com valores de PSA entre 2.6 e 10.0 ng/ml. Radiologia Brasileira, 44, 205-209.
https://doi.org/10.1590/S0100-39842011000400003

[4]   Brasil. Ministério da Saúde. Estimativa 2014: Incidência de Câncer no Brasil. Instituto Nacional de Câncer José Alencar Gomes da Silva, Coordenação de Pre- venção e Vigilância. INCA, Rio de Janeiro.
http://www.inca.gov.br/rbc/n_60/v01/pdf/11-resenha-estimativa-2014-incidencia-de-cancer-no-brasil.pdf

[5]   Nassif, A.E., Radaelli, M.R., Lins, L.F.C. and Angelo, V.F. (2013) Utilização do Antígeno Prostático Específico no Diagnóstico do Câncer de Próstata. Brazilian Journal of Surgery and Clinical Research, 5, 17-21.

[6]   Akin, Y., et al. (2017) Preliminary Assessment of Neck Circumference in Benign Prostatic Hyperplasia in Patients with Metabolic Syndrome. International Brazilian Journal of Urology, 43, 95-103.

[7]   Gimba, E.R.P. (2013) Além da era do PSA: Novos biomarcadores para câncer de próstata. Urologia Essencial, 3, 4-11.

[8]   Carter, R.H.B., Ferrucci, L., Kettermann, A., Landis, S.P., Wright, E.J., Epstein, J.I., Trock, B.J. and Metter, E.J. (2006) Detection of Life-Threatening Prostate Cancer with Prostate-Specific Antigen Velocity during a Window of Curability. Journal of the National Cancer Institute, 98, 1521-1527.
https://doi.org/10.1093/jnci/djj410

[9]   Sócrates de Castro, H.A., Lared, W., Shigueoka, D.C., Mourão, J.E. and Ajzen, S. (2011) Contribuição da densidade do PSA para predizer o câncer da próstata em pacientes com valores de PSA entre 2.6 e 10.0 ng/ml. Radiologia Brasileira, 4, 205-209.
https://doi.org/10.1590/S0100-39842011000400003

[10]   Moreira, H.A. (2015) Um novo índice para detecção do câncer de próstata (razão entre densidade do PSA e PSA livre sobre o PSA total). Tese de Doutorado, Almeida SHM, Orientador, 15.

[11]   Netto Jr., N.R. and Wroclawski, E.R. (2000) Urologia fundamentos para o clínico. Editora Sarvier, 216.

[12]   Rhoden, E.L. and Averbeck, M.A. (2010) Câncer de próstata localizado. Revista da AMRIGS, Porto Alegre, 54, 92-99.

[13]   Fernandes, M.V., Martins, J.T., Cardelli, A.A.M., Marcon, S.S. and Ribeiro, R.P. (2014) Perfil Epidemiológico do Homem com Câncer de Próstata Atendido em um Hospital Universitário. Cogitare Enfermagem, 19, 333-340.

[14]   Nassif, A.E. (2009) Análise do valor prognóstico dos marcadores imunohisto- químicos P27, MIB1 e CD34 no carcinoma de próstata localizado. Curitiba. Dis- sertação de Doutorado, Setor de Ciências da Saúde, Universidade Federal do Pa- raná.

[15]   Oesterling, J.E., Martin, S.K., Bergstrahl, E.J. and Lowe, F.C. (1993) The Use of Prostate-Specific Antigen in Staging Patients with Newly Diagnosed Prostate Cancer. JAMA, 269, 57-60.
https://doi.org/10.1001/jama.1993.03500010067033

[16]   Gomes, S.R., Melo, D.A., Soares, C.P.A., Motta, C.E., Benchimol, N.R.A. and Rainho, C.A.C. (2015) Análise da influência da densidade do PSA > 0.15 na progressão do câncer de próstata nos pacientes em vigilância ativa. Urominas- Revista Cientifica de Urologia da SBU-MG, 54-60.

 
 
Top